✦ LIBER ✦

7124 Association between time to disease progression (TDP) endpoints and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

✍ Scribed by Delea, T.; Khuu, A.; Kay, A.; Zheng, J.; Baladi, J.F.

Book ID: 121934454
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 51 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(09)71457-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O5 Progression free survival (PFS) and o

O5 Progression free survival (PFS) and overall survival (OS) in patients receiving 3 targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC)

✍ Iacovelli, R.; Milella, M.; Santoni, M.; Di Lorenzo, G.; Cerbone, L.; Ortega, C. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 172 KB

1006 ORAL Prognostic Factors for Progres

1006 ORAL Prognostic Factors for Progression-free Survival (PFS), Overall Survival (OS), and Long-term OS (LT-OS) With Sunitinib in 1,059 Patients, Treated on Clinical Trials, With Metastatic Renal Cell Carcinoma (mRCC)

✍ R.J. Motzer; B. Escudier; R. Bukowski; B.I. Rini; T.E. Hutson; C.H. Barrios; X. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 61 KB

1768 PROGRESSION-FREE AND OVERALL SURVIV

1768 PROGRESSION-FREE AND OVERALL SURVIVAL OF PATIENTS TREATED WITH PRESURGICAL SUNITINIB PRIOR TO CYTOREDUCTIVE NEPHRECTOMY (CN) IN CLEAR CELL SYNCHRONOUS METASTATIC RENAL CELL CARCINOMA (MRCC)

✍ Bex, Axel; Blank, Christian; Chowdhury, Simon; Nichol, David; Peters, John; Hore 📂 Article 📅 2011 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 54 KB

The association of pre-treatment neutrop

The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma

✍ Daniel Keizman; Maya Ish-Shalom; Peng Huang; Mario A. Eisenberger; Roberto Pili; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 310 KB

PCN200 Using A Weibull Parametric Model

PCN200 Using A Weibull Parametric Model for Failure-Time Data to Assess Progression-Free Survival as A Surrogate Endpoint for Overall Survival in A Trial of Patients with Metastatic Renal Cell Carcinoma

✍ Negrier, S.; Bushmakin, A.G.; Cappelleri, J.C.; Charbonneau, C.; Sandin, R.; Mic 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

3021 POSTER Association between exposure

3021 POSTER Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE)

✍ A. Grothey; M. Sugrue; E. Hedrick; D. Purdie; P. Chiruvolu; W. Dong; D. Sargent; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 76 KB